US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Polyrizon Ltd.

0.3300

+0.01003.12%

Post-market: 0.3230-0.0070-2.12%18:48 EDT

Volume:42.86K

Turnover:14.15K

Market Cap:13.14M

PE:- -

High:0.3450

Open:0.3210

Low:0.3154

Close:0.3200

Loading ...

Overview Company News Filings

Polyrizon appoints Michal Meir as senior director, regulatory & clinical affairs

Polyrizon Appoints DR. Michal Meir as Senior Director of Regulatory and Clinical Affairs

THOMSON REUTERS

Press Release: Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Polyrizon Shares Surge on Impending Clinical Trial

Polyrizon Collaborating With Eurofins CDMO for Clinical Trial of Allergy Blocker; Shares Jump

MT Newswires Live

Polyrizon's Moving Forward With Expected 2025 Clinical Trial - Entered Manufacturing Agreement for Its Pl-14 Allergy Blocker

THOMSON REUTERS

Polyrizon Announces Appointment of Vp of Regulatory Affairs and Quality Assurance

THOMSON REUTERS

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Polyrizon Enters Into Gmp Manufacturing Agreement for Ctm Supply of Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

THOMSON REUTERS

Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)

BRIEF-Polyrizon Announces Closing Of $4.2 Mln IPO

Polyrizon opens at $1.64, IPO priced at $4.38 per unit

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

THOMSON REUTERS

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Top Midday Decliners

MT Newswires Live

Polyrizon Shares Sink in Nasdaq Debut

MT Newswires Live

Polyrizon Prices $4.2 Million IPO

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PLRZ/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLRZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":0.329999,"timestamp":1745438400000,"preClose":0.32,"halted":0,"volume":42864,"hourTrading":{"tag":"盘后","latestPrice":0.323,"preClose":0.329999,"latestTime":"18:48 EDT","volume":140,"amount":45.305,"timestamp":1745448539733},"delay":0,"floatShares":37529021,"shares":39811100,"eps":0,"marketStatus":"Closed","change":0.009999,"latestTime":"04-23 16:00:00 EDT","open":0.321,"high":0.345,"low":0.3154,"amount":14152.76093664,"amplitude":0.0925,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745481600000},"marketStatusCode":5,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":0.32,"preHourTrading":{"tag":"盘前","latestPrice":0.345,"preClose":0.3351,"latestTime":"09:24 EDT","volume":2109,"amount":674.95497495,"timestamp":1745414673539},"postHourTrading":{"tag":"盘后","latestPrice":0.323,"preClose":0.329999,"latestTime":"18:48 EDT","volume":140,"amount":45.305,"timestamp":1745448539733},"volumeRatio":0.763376},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","floatShares":37529021,"roa":"-26.65%","roe":"-57.83%","lyrEps":0,"volumeRatio":0.763376,"shares":39811100,"dividePrice":0,"high":0.345,"amplitude":0.0925,"preClose":0.32,"low":0.3154,"week52Low":0.2806,"pbRate":"2.49","week52High":4.8,"institutionHeld":0,"latestPrice":0.329999,"eps":0,"divideRate":0,"volume":42864,"delay":0,"ttmEps":0,"open":0.321,"prevYearClose":2.17,"prevWeekClose":0.3559,"prevMonthClose":0.369,"prevQuarterClose":0.369,"fiveDayClose":0.378,"twentyDayClose":0.54,"sixtyDayClose":1.38},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLRZ\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492244651","title":"Polyrizon appoints Michal Meir as senior director, regulatory & clinical affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492244651","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492244651?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:30","pubTimestamp":1734611443,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced the appointment of Dr. Michal Meir, Senior Consultant at MedTech, as Senior Director of Regulatory and Clinical Affairs....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-appoints-michal-meir-as-senior-director-regulatory-clinical-affairs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-appoints-michal-meir-as-senior-director-regulatory-clinical-affairs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2492412104","title":"Polyrizon Appoints DR. Michal Meir as Senior Director of Regulatory and Clinical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492412104","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492412104?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:22","pubTimestamp":1734610920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABPZKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2492912107","title":"Press Release: Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492912107","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492912107?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:22","pubTimestamp":1734610920,"startTime":"0","endTime":"0","summary":"Raanana, Israel, Dec. 19, 2024  -- Polyrizon Ltd.  , a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product development.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","PLRZ","TM","03160","BK4588","BK4099","BK4555"],"gpt_icon":1},{"id":"2492913875","title":"Polyrizon Shares Surge on Impending Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2492913875","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492913875?lang=en_us&edition=fundamental","pubTime":"2024-12-19 00:02","pubTimestamp":1734537720,"startTime":"0","endTime":"0","summary":"Shares of Polyrizon more than quadrupled intraday after the biotech company said it is moving forward with an allergy blocker clinical trial next year.The stock on Wednesday gained as much as 357% to $4.80, a new 52-week high, and was halted soon after the open for volatility. More recently it was up 216% to $3.32.The Israel-based biotech company said it has entered a manufacturing agreement for its PL-14 allergy blocker with Eurofins CDMO Amatsiaquitaine S.A.S., an EU-based GMP manufacturing facility. The collaboration will support its upcoming clinical trial for the nasal spray treatment, expected to start next year, Polyrizon said.The company added that the manufacturing site is set to support the trial, offering development programs in line with U.S. and European regulatory standards.Polyrizon previously announced the upcoming trial and manufacturing agreement earlier this month.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":1},{"id":"2492183749","title":"Polyrizon Collaborating With Eurofins CDMO for Clinical Trial of Allergy Blocker; Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2492183749","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492183749?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:22","pubTimestamp":1734528159,"startTime":"0","endTime":"0","summary":"Polyrizon  said Wednesday it has entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a European-based GMP-certified manufacturer, to supply clinical trial material for its PL-14 allergy blocker study expected to begin in 2025.The trial aims to evaluate the safety and efficacy of PL-14 as an allergy blocker, the company said.Polyrizon said the manufacturing site for the clinical trial material will meet US and European regulatory standards and provide high-quality development support for the 2025 trial.Polyrizon shares were 160% higher in premarket trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PLRZ","CDMO"],"gpt_icon":1},{"id":"2492011009","title":"Polyrizon's Moving Forward With Expected 2025 Clinical Trial - Entered Manufacturing Agreement for Its Pl-14 Allergy Blocker","url":"https://stock-news.laohu8.com/highlight/detail?id=2492011009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492011009?lang=en_us&edition=fundamental","pubTime":"2024-12-18 19:25","pubTimestamp":1734521100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUAC1R5G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2491325955","title":"Polyrizon Announces Appointment of Vp of Regulatory Affairs and Quality Assurance","url":"https://stock-news.laohu8.com/highlight/detail?id=2491325955","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491325955?lang=en_us&edition=fundamental","pubTime":"2024-12-13 19:25","pubTimestamp":1734089100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nTUA4GVMLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2491325432","title":"Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance","url":"https://stock-news.laohu8.com/highlight/detail?id=2491325432","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491325432?lang=en_us&edition=fundamental","pubTime":"2024-12-13 19:25","pubTimestamp":1734089100,"startTime":"0","endTime":"0","summary":"Raanana, Israel, Dec. 13, 2024  -- Polyrizon Ltd.  , a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins’ Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance . This strategic appointment reflects Polyrizon’s ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions.Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and implementing regulatory strategies. His deep understanding of the global regulatory landscape will play a vital role in ensuring Polyrizon’s compliance with international standards and achieving its strategic goals.\"We are excited to strengthen our team with proven expertise in RA/QA to support Polyrizon’s mission of delivering safe and effective solutions to market,” s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-announces-appointment-vp-regulatory-112500190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2488568676","title":"Polyrizon Enters Into Gmp Manufacturing Agreement for Ctm Supply of Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2488568676","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488568676?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:02","pubTimestamp":1733144520,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nTUA8B0TTC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2479975307","title":"Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479975307","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479975307?lang=en_us&edition=fundamental","pubTime":"2024-10-31 01:50","pubTimestamp":1730310600,"startTime":"0","endTime":"0","summary":"NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.2 Million  Initial Public Offering for Polyrizon Ltd. .Polyrizon Ltd. is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Their proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a \"biological mask\" with a thin shield containment barrier in the nasal cavity. They're are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. They refer to their addit","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KTsNJd83IplE1dXaAnTAig--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/8a29d792d17fad9b689e38945272dd73","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KTsNJd83IplE1dXaAnTAig--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/8a29d792d17fad9b689e38945272dd73"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aegis-capital-corp-acted-sole-175000404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","NQmain","SQQQ","QID","IE00BGHQF748.EUR","LU2210150020.SGD","QLD","PSQ","BK4112","PLRZ","IE00BKPKM429.USD","BK4588","IPO","LU2095319765.USD",".IXIC","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","TQQQ","MNQmain"],"gpt_icon":1},{"id":"2479688787","title":"BRIEF-Polyrizon Announces Closing Of $4.2 Mln IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2479688787","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479688787?lang=en_us&edition=fundamental","pubTime":"2024-10-30 23:09","pubTimestamp":1730300958,"startTime":"0","endTime":"0","summary":"Oct 30 (Reuters) - Polyrizon Ltd   :   * POLYRIZON ANNOUNCES CLOSING OF $4.2 MILLION INITIAL PUBLIC OFFERINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2479261787","title":"Polyrizon opens at $1.64, IPO priced at $4.38 per unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2479261787","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479261787?lang=en_us&edition=fundamental","pubTime":"2024-10-30 23:05","pubTimestamp":1730300746,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) priced 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-opens-at-1-64-ipo-priced-at-4-38-per-unit?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-opens-at-1-64-ipo-priced-at-4-38-per-unit?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2479078155","title":"Polyrizon Announces Closing of $4.2 Million Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2479078155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479078155?lang=en_us&edition=fundamental","pubTime":"2024-10-30 22:28","pubTimestamp":1730298534,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241030:nTUA7MB0JK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2479778449","title":"Polyrizon Announces Closing of $4.2 Million Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2479778449","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479778449?lang=en_us&edition=fundamental","pubTime":"2024-10-30 22:28","pubTimestamp":1730298480,"startTime":"0","endTime":"0","summary":"Raanana, Israel, Oct. 30, 2024  -- Polyrizon Ltd. , a development stage biotech company specializing in the development of innovative medical device hydrogels, today announced the closing of its underwritten initial public offering of 958,903 units at a combined public offering price of$4.38 per unit, with each unit each consisting of one ordinary share and three warrants to purchase one ordinary share per warrant, with an initial exercise price of$4.38 per share. Aggregate gross proceeds were $4.2 million, prior to deducting underwriting discounts and offering expenses.In addition, PLRZ has granted Aegis Capital Corp.  a 45-day option to purchase up to 143,835 additional units, equal to 15% of the number of ordinary shares sold in the offering solely to cover over-allotments, if any. If Aegis exercises the option in full, the total gross proceeds of the offering including the overallotment are expected to be approximately $4.82 million before deducting underwriting discounts and commi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-announces-closing-4-2-142800799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2479440237","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2479440237","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479440237?lang=en_us&edition=fundamental","pubTime":"2024-10-30 02:04","pubTimestamp":1730225043,"startTime":"0","endTime":"0","summary":"1847 Holdings  said Tuesday it priced a securities offering targeting gross proceeds of $11.1 million.Shares slumped 65%, with intraday trading volume at over 16.1 million compared with a daily average of about 1.2 million.Polyrizon  debuted on the Nasdaq on Tuesday as it priced a $4.2 million initial public offering.Shares of the development-stage biotech company plunged 66% as intraday trading volume soared to over 1.18 million.Janus International Group's  shares sank 31% amid heavy trading after the company reported a year-over-year decline in fiscal Q3 earnings and sales, missing expectations.The company also cut its full-year 2024 revenue outlook.More than 10.1 million shares traded intraday compared with a daily average of about 2.3 million.Price: 0.44, Change: -0.82, Percent Change: -65.24","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4086","JBI","LU1169589451.USD","PLRZ","LU1169590202.USD","BK4590","BK4206","EFSH"],"gpt_icon":0},{"id":"2479233577","title":"Polyrizon Shares Sink in Nasdaq Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2479233577","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479233577?lang=en_us&edition=fundamental","pubTime":"2024-10-30 00:05","pubTimestamp":1730217953,"startTime":"0","endTime":"0","summary":"Polyrizon  shares fell in their Nasdaq trading debut on Tuesday after the development-stage biotech company priced its $4.2 million initial public offering.The stock was down about 66% in recent trading after opening at $1.64.Polyrizon priced its IPO of 958,903 units at a combined price of $4.38 per unit, with each unit each consisting of one share and three warrants to buy one share per warrant, with an initial exercise price of $4.38 per share.Aegis Capital has a 45-day option to acquire up to 143,835 additional units. The offering is expected to close Wednesday.Price: 1.47, Change: -2.91, Percent Change: -66.44","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4112","NDAQ","QLD","BK4585","MNQmain","IE00BGHQF748.EUR","IE00B64PRP62.GBP","TQQQ","NQmain","LU2210150020.SGD","QID","PSQ","IE00B3QW5Z07.USD","LU2210149790.SGD","SQQQ",".IXIC","LU2095319765.USD","PLRZ","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2479784684","title":"Polyrizon Prices $4.2 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2479784684","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479784684?lang=en_us&edition=fundamental","pubTime":"2024-10-29 17:33","pubTimestamp":1730194411,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) said Monday that it priced its underwritten initial public offering of 958,903 units at $4.38 per unit for expected gross proceeds of $4.2 million.Each unit consists of one ordinary s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PLRZ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":57,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLRZ\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLRZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLRZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLRZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLRZ","date":"2025-04-22","current":-0.8959,"percent":1,"low":-29.515607,"twenty":-5.263229,"median":-3.569805,"eighty":-1.655245,"high":-0.8959,"avg":-4.0708,"sd":3.182257,"marketCap":1384166},"quantilePoints":[{"date":"2024-10-31","current":-13.097935,"twenty":-22.948538,"median":-13.097935,"eighty":-12.489816,"marketCap":7858761},{"date":"2024-11-08","current":-3.903419,"twenty":-12.692522,"median":-4.690878,"eighty":-4.316449,"marketCap":3891709},{"date":"2024-11-15","current":-2.661127,"twenty":-9.219549,"median":-4.249136,"eighty":-3.530862,"marketCap":2653144},{"date":"2024-11-22","current":-2.985655,"twenty":-4.737156,"median":-3.736612,"eighty":-3.09924,"marketCap":2976698},{"date":"2024-11-29","current":-3.042447,"twenty":-4.451075,"median":-3.375089,"eighty":-3.037515,"marketCap":3033320},{"date":"2024-12-06","current":-3.212824,"twenty":-4.383762,"median":-3.342636,"eighty":-3.042447,"marketCap":3203186},{"date":"2024-12-13","current":-3.375088,"twenty":-4.191157,"median":-3.358862,"eighty":-3.047315,"marketCap":3364963},{"date":"2024-12-20","current":-7.561496,"twenty":-4.383762,"median":-3.375088,"eighty":-3.07146,"marketCap":7538812},{"date":"2024-12-27","current":-5.744141,"twenty":-5.095085,"median":-3.407542,"eighty":-3.090153,"marketCap":5726909},{"date":"2025-01-03","current":-5.938858,"twenty":-6.101122,"median":-3.569805,"eighty":-3.132991,"marketCap":5921041},{"date":"2025-01-10","current":-4.997727,"twenty":-6.159537,"median":-3.796975,"eighty":-3.146231,"marketCap":4982734},{"date":"2025-01-17","current":-6.142316,"twenty":-6.098128,"median":-3.933764,"eighty":-3.167391,"marketCap":6123889},{"date":"2025-01-24","current":-5.889893,"twenty":-6.192801,"median":-4.333277,"eighty":-3.193353,"marketCap":5872223},{"date":"2025-01-31","current":-5.553327,"twenty":-6.125488,"median":-4.527162,"eighty":-3.214122,"marketCap":5536667},{"date":"2025-02-07","current":-4.552045,"twenty":-6.087615,"median":-4.738105,"eighty":-3.227753,"marketCap":4538389},{"date":"2025-02-14","current":-4.711914,"twenty":-6.064471,"median":-4.705652,"eighty":-3.245278,"marketCap":4697778},{"date":"2025-02-21","current":-4.522596,"twenty":-6.049761,"median":-4.627772,"eighty":-3.258259,"marketCap":4509028},{"date":"2025-02-28","current":-3.707687,"twenty":-6.000655,"median":-4.535397,"eighty":-3.316674,"marketCap":3696564},{"date":"2025-03-07","current":-3.460732,"twenty":-5.929065,"median":-4.501561,"eighty":-3.241954,"marketCap":3450350},{"date":"2025-03-14","current":-1.846098,"twenty":-5.873065,"median":-4.396383,"eighty":-3.213473,"marketCap":2852222},{"date":"2025-03-21","current":-1.508371,"twenty":-5.793429,"median":-4.291207,"eighty":-3.160314,"marketCap":2330433},{"date":"2025-03-28","current":-1.353625,"twenty":-5.705978,"median":-3.977976,"eighty":-3.07146,"marketCap":2091350},{"date":"2025-04-04","current":-0.974631,"twenty":-5.536499,"median":-3.903419,"eighty":-3.030526,"marketCap":1505805},{"date":"2025-04-11","current":-0.980061,"twenty":-5.4398,"median":-3.702849,"eighty":-2.640357,"marketCap":1514194},{"date":"2025-04-17","current":-0.985491,"twenty":-5.322255,"median":-3.619184,"eighty":-1.846098,"marketCap":1522583},{"date":"2025-04-22","current":-0.8959,"twenty":-5.263229,"median":-3.569805,"eighty":-1.655245,"marketCap":1384166}],"updateTime":1745461985162}}}